Medicare Enrolled
Dr. Grigorios Chrysofakis, MD
Hematology & Oncology · Sacramento, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Chrysofakis from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Chrysofakis?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Chrysofakis
Dr. Grigorios Chrysofakis is a hematology & oncology specialist in Sacramento, CA, with 14 years of NPI registration. Based on federal Medicare data, Dr. Chrysofakis performed 34,461 Medicare services across 850 unique beneficiaries.
Between the years covered by Open Payments, Dr. Chrysofakis received a total of $5,105 from 37 pharmaceutical and/or device companies across 230 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Chrysofakis is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 14 years in practice
▲ Top 18% volume in CA
$5,105 industry payments
Medicare Practice Summary
Medicare Utilization ↗34,461
Medicare services
Top 18% in CA for hematology & oncology
850
Unique beneficiaries
$4
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~2,462 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
20,250 | $1 | $3 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
9,300 | $0 | $3 |
| Anti-nausea injection (ondansetron/Zofran) | 1,408 | $0 | $0 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
940 | $0 | $0 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
394 | $67 | $198 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
286 | $8 | $22 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
250 | $104 | $287 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
175 | $26 | $83 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
175 | $117 | $379 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
153 | $66 | $189 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
143 | $7 | $8 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
136 | $10 | $29 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
126 | $14 | $44 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
111 | $57 | $184 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
103 | $25 | $81 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
92 | $12 | $38 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
63 | $99 | $272 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
60 | $17 | $56 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
52 | $1 | $2 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
47 | $108 | $358 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
46 | $131 | $431 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
45 | $57 | $191 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
43 | $1 | $2 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
35 | $11 | $36 |
| Office visit for established patient An office visit for an existing patient that may not require the healthcare professional to be present. |
28 | $20 | $62 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
60.5% high complexity
34.9% medium
4.6% routine
Industry Payment Transparency
Open Payments through 2024 ↗$5,105
Total received (2018-2024)
Avg $729/year across 7 years
Top 43% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
37
Companies
230
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$4,049 (79.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$1,056 (20.7%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,374
2023
$1,243
2022
$1,388
2021
$616
2020
$44
2019
$148
2018
$293
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
PFIZER INC.
$288
Astellas Pharma US Inc
$148
Novartis Pharmaceuticals Corporation
$135
Genentech USA, Inc.
$115
Janssen Biotech, Inc.
$100
Celgene Corporation
$94
GlaxoSmithKline, LLC.
$70
AstraZeneca Pharmaceuticals LP
$63
Merck Sharp & Dohme LLC
$62
E.R. Squibb & Sons, L.L.C.
$56
Deciphera Pharmaceuticals Inc.
$54
ABBVIE INC.
$49
ARRAY BIOPHARMA INC
$40
SpringWorks Therapeutics, Inc.
$30
BeiGene USA, Inc.
$26
Regeneron Healthcare Solutions, Inc.
$24
SERVIER PHARMACEUTICALS LLC
$20
Top 3 companies account for 41.6% of 2024 payments
All-time payments by company (2018-2024) ›
PFIZER INC.
$841
Astellas Pharma US Inc
$671
Amgen Inc.
$358
Seagen Inc.
$346
E.R. Squibb & Sons, L.L.C.
$316
Novartis Pharmaceuticals Corporation
$304
Genentech USA, Inc.
$256
Pharmacyclics LLC, An AbbVie Company
$233
Celgene Corporation
$204
GlaxoSmithKline, LLC.
$171
Janssen Biotech, Inc.
$135
Kite Pharma, Inc.
$129
Merck Sharp & Dohme LLC
$123
Gilead Sciences, Inc.
$96
Daiichi Sankyo Inc.
$93
Lilly USA, LLC
$91
Deciphera Pharmaceuticals Inc.
$77
ARRAY BIOPHARMA INC
$67
AstraZeneca Pharmaceuticals LP
$63
ABBVIE INC.
$61
SERVIER PHARMACEUTICALS LLC
$60
Alexion Pharmaceuticals, Inc.
$45
Sumitomo Pharma America, Inc.
$40
GE HealthCare
$36
EISAI INC.
$36
SpringWorks Therapeutics, Inc.
$30
BeiGene USA, Inc.
$26
Regeneron Healthcare Solutions, Inc.
$24
Rigel Pharmaceuticals, Inc.
$23
AbbVie Inc.
$23
MorphoSys, US Inc.
$22
Myovant Sciences Inc.
$22
Global Blood Therapeutics, Inc.
$20
Pharmacyclics LLC, an AbbVie Company
$19
Merck Sharp & Dohme Corporation
$16
EMD Serono, Inc.
$14
GENZYME CORPORATION
$13
Top 3 companies account for 36.6% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · Alecensa · BOSULIF · BRAFTOVI · BRUKINSA · CYRAMZA · DARZALEX · ELREXFIO · ENHERTU · EPKINLY · ERLEADA · Enhertu · Fabhalta · IBRANCE · IMBRUVICA · INJECTAFER · INLYTA · Imbruvica · Itovebi · JEMPERLI · KEYTRUDA · Kyprolis · LIBTAYO · LORBRENA · LUMAKRAS · LUPRON DEPOT · LUTATHERA · LYNPARZA · Lenvima · Lunsumio · MONJUVI · Nplate · OGSIVEO · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · OXBRYTA · PADCEV · PIQRAY · PLUVICTO · PROMACTA · Padcev · Perjeta · Phesgo · Pomalyst · QINLOCK · REBLOZYL · SARCLISA · SCEMBLIX · TUKYSA · Tavalisse · Tecentriq · Tibsovo · Trodelvy · ULTOMIRIS · VENCLEXTA · VERZENIO · Venclexta · Vyloy · XTANDI · Xospata · Xtandi · Yescarta · ZEJULA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (79%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
83
Per 100K population
5.2
County median income
$88,724
Nearest hospital
SUTTER MEDICAL CENTER, SACRAMENTO
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Chrysofakis is a mixed practice specialist, with above-average Medicare volume (top 18% in CA), with low-engagement industry engagement.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Chrysofakis experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Chrysofakis performed 20,250 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Chrysofakis receive payments from pharmaceutical companies?
Yes. Dr. Chrysofakis received a total of $5,105 from 37 companies across 230 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Chrysofakis's costs compare to other hematology & oncology specialists in Sacramento?
Dr. Chrysofakis's average Medicare payment per service is $4. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Chrysofakis) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Sacramento
Browse hematology & oncology specialists in Sacramento ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
Astellas Pharma US Inc Payments to Doctors
See all physicians who received payments from Astellas Pharma US Inc.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology